Four Decades for Justice
Cravath represents and advises clients on a range of high‑stakes matters relating to the federal False Claims Act (FCA) and similar state legislation, which permit private individuals to initiate lawsuits alleging that the government has been defrauded and to claim a share of any resulting recovery.
Our experience in this area includes successfully defending corporations that have been sued under the FCA, conducting internal investigations and crafting and implementing compliance and remedial programs to protect clients from future FCA exposure. We have represented clients in qui tam litigation, in which we have obtained early dismissal or resolution of relator suits. We have also represented clients in connection with other matters relating to the FCA, such as employment retaliation claims asserted by whistleblowers, related shareholder litigation and SEC investigations and various corporate governance and disclosure issues.
Cravath’s attorneys have previously held senior positions in the Department of Justice and the Securities and Exchange Commission. Our team also includes lawyers with extensive experience in highly regulated industries most at‑risk for FCA suits, including pharmaceuticals and financial services.
Our experience in this area includes successfully defending corporations that have been sued under the FCA, conducting internal investigations and crafting and implementing compliance and remedial programs to protect clients from future FCA exposure. We have represented clients in qui tam litigation, in which we have obtained early dismissal or resolution of relator suits. We have also represented clients in connection with other matters relating to the FCA, such as employment retaliation claims asserted by whistleblowers, related shareholder litigation and SEC investigations and various corporate governance and disclosure issues.
Cravath’s attorneys have previously held senior positions in the Department of Justice and the Securities and Exchange Commission. Our team also includes lawyers with extensive experience in highly regulated industries most at‑risk for FCA suits, including pharmaceuticals and financial services.
Deals & Cases
September 26, 2022
On September 13, 2022, Judge Kimba M. Wood of the United States District Court for the Southern District of New York ruled in favor of Cravath client Novartis, dismissing with prejudice a third amended complaint filed by Relator Steven M. Camburn. In the complaint, Relator asserted claims under the False Claims Act and analogous state laws based on Novartis’s promotion of the multiple sclerosis drug Gilenya.
Deals & Cases
September 26, 2022
On September 13, 2022, Judge Kimba M. Wood of the United States District Court for the Southern District of New York ruled in favor of Cravath client Novartis, dismissing with prejudice a third amended complaint filed by Relator Steven M. Camburn. In the complaint, Relator asserted claims under the False Claims Act and analogous state laws based on Novartis’s promotion of the multiple sclerosis drug Gilenya.
Explore
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. © 2023 Cravath, Swaine & Moore LLP.